Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2017 from OUS - Translational Cancer Therapy
18 publications found
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694, PubMed 28977905
Is detection of intraperitoneal exfoliated tumor cells after surgical resection of rectal cancer a prognostic factor of survival?
BMC Cancer, 17 (1), 406
DOI 10.1186/s12885-017-3365-7, PubMed 28592327
Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
Acta Oncol, 56 (6), 813-818
DOI 10.1080/0284186X.2017.1287951, PubMed 28464745
Atp8 is in the ground pattern of flatworm mitochondrial genomes
BMC Genomics, 18 (1), 414
DOI 10.1186/s12864-017-3807-2, PubMed 28549457
The Results of Stricter Inclusion Criteria in an Immunomagnetic Detection Study of Micrometastatic Cells in Bone Marrow of Uveal Melanoma Patients - Relevance for Dormancy
Pathol Oncol Res, 25 (1), 255-262
DOI 10.1007/s12253-017-0355-7, PubMed 29098521
Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
Pigment Cell Melanoma Res, 30 (5), 467-476
DOI 10.1111/pcmr.12599, PubMed 28513992
Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
Ann Surg Oncol, 24 (7), 1916-1922
DOI 10.1245/s10434-017-5814-6, PubMed 28224367
Pathway-based classification of breast cancer subtypes
Front Biosci (Landmark Ed), 22, 1697-1712
DOI 10.2741/4566, PubMed 28410140
Interplay between Immune Checkpoint Proteins and Cellular Metabolism
Cancer Res, 77 (6), 1245-1249
DOI 10.1158/0008-5472.CAN-16-1647, PubMed 28246276
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
Oncotarget, 8 (44), 76290-76304
DOI 10.18632/oncotarget.19350, PubMed 29100312
Extreme conservation of miRNA complements in opisthorchiids
Parasitol Int, 66 (6), 773-776
DOI 10.1016/j.parint.2017.09.006, PubMed 28916307
Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
Oncotarget, 8 (44), 76921-76934
DOI 10.18632/oncotarget.20217, PubMed 29100358
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma
Exp Mol Pathol, 103 (2), 218-228
DOI 10.1016/j.yexmp.2017.10.001, PubMed 29050853
GSuite HyperBrowser: integrative analysis of dataset collections across the genome and epigenome
Gigascience, 6 (7), 1-12
DOI 10.1093/gigascience/gix032, PubMed 28459977
A comprehensive profile of circulating RNAs in human serum
RNA Biol, 15 (2), 242-250
DOI 10.1080/15476286.2017.1403003, PubMed 29219730
A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained in vitro and in vivo stemness properties
Exp Cell Res, 352 (2), 218-224
DOI 10.1016/j.yexcr.2017.02.005, PubMed 28189639
Increased expression of CD44 is associated with more aggressive behavior in clear cell renal cell carcinoma
Biomark Med, 12 (1), 45-61
DOI 10.2217/bmm-2017-0142, PubMed 29243496